Birchview Capital »

Illumina shares owned by Birchview Capital

Quarter-by-quarter ownership of Illumina (ILMN) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Illumina

Tip: Access up to 7 years of quarterly data

All positions including Illumina held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Illumina by Birchview Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $787k 6.0k 131.16

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Compass Therapeutics (CMPX)
Stoke Therapeutics (STOK)
Lam Research Corporation Com New (LRCX)
Olema Pharmaceuticals (OLMA)
Structure Therapeutics Spons Adr (GPCR)
Protagonist Therapeutics (PTGX)
ACADIA Pharmaceuticals (ACAD)
Encana Corporation (OVV)
Prothena Corp SHS (PRTA)
Solid Biosciences Com New (SLDB)
Neurocrine Biosciences (NBIX)
Amicus Therapeutics (FOLD)
Bicycle Therapeutics Sponsored Ads (BCYC)

View all positions for Birchview Capital

Top funds holding Illumina

Capital World Investors
BlackRock
Vanguard Group
State Street Corporation
Loomis, Sayles and
WCM Investment Management
Corvex Management
Sessa Capital IM
AQR Capital Management
Geode Capital Management
Invesco
Henderson Group
PRIMECAP Management Company
Citadel Advisors
Baillie Gifford & Co

View all funds holding Illumina